Tag: Nasdaq:SUPN
Supernus to Host First Quarter 2021 Financial Results Conference Call
ROCKVILLE, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing...
Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of...
Qelbree (viloxazine extended-release capsules) represents the first novel non-stimulant treatment for ADHD in a decade Supernus plans to make Qelbree available in...